Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of A-101 for Common Warts
NCT03812510Phase 3Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrogen peroxide in common warts, sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts. Started Feb 2019; status: completed.
02
Drugs
hydrogen peroxide
03
Conditions
common warts
Beyond the preview
Go deeper on NCT03812510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812510.